Dogwood Therapeutics, Inc. Deferred Income Tax Expense (Benefit)
Dogwood Therapeutics, Inc. (DWTX) reported Deferred Income Tax Expense (Benefit) of -$2.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-08-14
- Dogwood Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2026-06-30 was -$2.48M, a 1664995.30% decline year-over-year.
- Dogwood Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2026-03-31 was $1.19K, a 99.37% decline year-over-year.
- Dogwood Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2025-12-31 was $31.84K.
- Dogwood Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2025-09-30 was -$1.44K.
- Dogwood Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2025 was $221.10K.
- Dogwood Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2024 was -$503.00.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.48M 10-Q · filed 2026-08-14 | -$2.48M 10-Q · filed 2026-08-14 | -$2.45M derived: sum of 3 quarters · filed 2026-08-14 | -$2.45M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.19K 10-Q · filed 2026-05-15 | $33.03K derived: sum of 2 quarters · filed 2026-05-15 | $31.60K derived: sum of 3 quarters · filed 2026-05-15 | $31.75K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $31.84K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $30.41K derived: sum of 2 quarters · filed 2026-03-18 | $30.55K derived: sum of 3 quarters · filed 2026-08-14 | $221.10K 10-K · filed 2026-03-18 |
| 2025-09-30 | -$1.44K 10-Q · filed 2025-11-07 | -$1.29K derived: sum of 2 quarters · filed 2026-08-14 | $189.25K 10-Q · filed 2025-11-07 | $188.75K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $149.00 10-Q · filed 2026-08-14 | $190.69K 10-Q · filed 2026-08-14 | $190.19K derived: sum of 3 quarters · filed 2026-08-14 | $190.19K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $190.54K 10-Q · filed 2026-05-15 | $190.04K derived: sum of 2 quarters · filed 2026-05-15 | $190.04K derived: sum of 3 quarters · filed 2026-05-15 | $190.04K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$503.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$503.00 derived: sum of 2 quarters · filed 2026-03-18 | -$503.00 derived: sum of 3 quarters · filed 2026-03-18 | -$503.00 10-K · filed 2026-03-18 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | $0.00 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |